With INO further proving the efficacy of electroporation, it has become even more likely that ONCS' next results will also be positive. Traders seem to be setting themselves up to duplicate their recent windfall in INO with ONCS. Do you think this trend will continue until ONCS reports their next results? Seems like a good strategy to me. However, I'm holding my shares in both companies.
consider the outside chance of accelerated approval...sarepta has twelve boys evaluable and they have a 60/40 chance of aa so if we show a response rate here of 45% then at least 60/40 chance and perhaps 70/30 chance of getting AA with 24 patients from pii and 23 from pi combined allows 43 patients evaluable
ONCS's past trial data is why I have invested so heavily in this company. True that INO efficacy does help but its the prior data that really make this compelling. The only negative, if there is any, is the sizes of their earlier trials. This years potential is huge with the upcoming data, especially in December with the Melanoma data.